Journals / Anadolu Kardiyoloji Dergisi / 2014 / Cilt: 14 - Sayı: 6

Could plasma asymmetric dimethylarginine level be a novel predictor beyond the classic predictors of stent restenosis?

Pages
491–497
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Plasma ADMA level ( β=0.536; OR: 1.710; CI: 1.022-2.861; p=0.041), C-reactive protein concentration (β=0.062; OR: 1.064; CI: 1.003-1.129; p=0.041), stent diameter ( β=-3.047; OR: 0.048; CI: 0.007-0.313; p=0.002) and length ( β=0.165; OR: 1.179; CI: 1.036-1.343; p=0.013) were foundto be the independent predictors of stent restenosis in logistic regression analysis.Conclusion: We conclude that plasma ADMA levels may be used as a novel marker for stent restenosis beyond the classic stent restenosismarkers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate the factors associated with coronary stent restenosis and if there is an association betweenplasma asymmetric dimethylarginine (ADMA) levels and stent restenosis.Methods: Ninety-one patients, who had a history of coronary bare metal stent implantation due to any cause in the last one year period, wereadmitted to this observational cross-sectional study.
📊
Key Findings & Data:Plasma ADMA levels were measured by using high performance liquid chromatography.
💡
Conclusion & Impact:Plasma ADMA level ( β=0.536; OR: 1.710; CI: 1.022-2.861; p=0.041), C-reactive protein concentration (β=0.062; OR: 1.064; CI: 1.003-1.129; p=0.041), stent diameter ( β=-3.047; OR: 0.048; CI: 0.007-0.313; p=0.002) and length ( β=0.165; OR: 1.179; CI: 1.036-1.343; p=0.013) were foundto be the independent predictors of stent restenosis in logistic regression analysis.Conclusion: We conclude that plasma ADMA levels may be used as a novel marker for stent restenosis beyond the classic stent restenosismarkers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to investigate the factors associated with coronary stent restenosis and if there is an association betweenplasma asymmetric dimethylarginine (ADMA) levels and stent restenosis.Methods: Ninety-one patients, who had a history of coronary bare metal stent implantation due to any cause in the last one year period, wereadmitted to this observational cross-sectional study. Coronary angiography was performed to all patients and quantitative angiography wasused to determine the presence of stent restenosis. Laboratory parameters and angiographic features that contribute to stent restenosis wereevaluated. Plasma ADMA levels were measured by using high performance liquid chromatography. Logistic regression analysis was used todetermine the independent factors of stent restenosis.Results: Angiographic restenosis was found in 35 patients (38.5%). Stent diameter (p=0.038) and left ventricular ejection fraction (p=0.023) werelower and stent implantation history due to acute coronary syndrome (p=0.029), plasma ADMA level (5.0±1.8x10 -4 mmol/L vs. 3.9±1.0x10 -4mmol/L, p=0.001), C-reactive protein concentration (p=0.016), white blood cell count (p=0.044) and stent length (p=0.005) were higher in patientswith restenosis. Plasma ADMA level ( β=0.536; OR: 1.710; CI: 1.022-2.861; p=0.041), C-reactive protein concentration (β=0.062; OR: 1.064; CI: 1.003-1.129; p=0.041), stent diameter ( β=-3.047; OR: 0.048; CI: 0.007-0.313; p=0.002) and length ( β=0.165; OR: 1.179; CI: 1.036-1.343; p=0.013) were foundto be the independent predictors of stent restenosis in logistic regression analysis.Conclusion: We conclude that plasma ADMA levels may be used as a novel marker for stent restenosis beyond the classic stent restenosismarkers.

🔖

Cite This Article

BAL, U. A., YILDIRIR, A., AYDINALP, A., KAYNAR, G., KANYILMAZ, S., MURAT, K., MÜDERRİSOĞLU, İ. H. (2022). Could plasma asymmetric dimethylarginine level be a novel predictor beyond the classic predictors of stent restenosis?. Anadolu Kardiyoloji Dergisi, Cilt: 14 - Sayı: 6, 491–497. https://ajindex.com/articles/437207

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rajagopal V, Rockson SG. Coronary restenosis: a review of mecha- nisms and management. Am J Med 2003
  2. [CrossRef] 2. Schulz R, Triggle CR. Role of NO in vascular smooth muscle and car- diac muscle function. Trends Pharmacol Sci 1994
  3. [CrossRef] 3. Marletta MA, Hurshman AR, Rusche KM. Catalysis by nitric oxide synthase. Curr Opin Chem Biol 1998
  4. [CrossRef] 4. Thanyasiri P, Kathir K, Celermajer DS, Adams MR. Endothelial dys- function and restenosis following percutaneous coronary inter- vention. Int J Cardiol 2007
  5. [CrossRef] 5. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989
  6. [CrossRef] 6. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995
  7. [CrossRef] 7. Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol 1998
  8. [CrossRef] 8. Jin JS, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol 1996
  9. [CrossRef] 9. Derkacz A, Protasiewicz M, Poreba R, Doroszko A, Poreba M, Antonowicz-Juchniewicz J, et al. Plasma asymmetric dimethylargi- nine predicts restenosis after coronary angioplasty. Arch Med Sci 2011
  10. [CrossRef] 10. Khalifa NM, Gad MZ, Hataba AA, Mahran LG. Changes in ADMA and TAFI levels after stenting in coronary artery disease patients. Mol Med Rep 2012
  11. Arı H, Arı S, Erdoğan E, Tiryakioğlu O, Üstündağ Y, Huysal K, et al. A novel predictor of restenosis and adverse cardiac events: asym- metric dimethylarginine. Heart Vessels 2010
  12. [CrossRef] 12. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010
  13. [CrossRef] 13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011
  14. [CrossRef] 14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCE